New Zealand PHARMAC Proposes Lifting Restrictions On Merck’s Fosamax; Reduces Subsidy For EC Aspirin
This article was originally published in PharmAsia News
PERTH, Australia - New Zealand's Pharmaceutical Management Agency has proposed lifting some of the restrictions on drugs classified for musculoskeletal system therapies, effective March 1, the agency announced Jan. 12
You may also be interested in...
Japanese drug maker looks to dexlansoprazole to help offset loses when Prevacid and anti-diabetic Actos go off patent this year.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).